Madrigal Pharmaceuticals Inc (MDGL) USD0.00010

Sell:$328.77Buy:$328.95$13.99 (4.03%)

NASDAQ:2.61%
Market closed | Prices delayed by at least 15 minutes
Sell:$328.77
Buy:$328.95
Change:$13.99 (4.03%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$328.77
Buy:$328.95
Change:$13.99 (4.03%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Key people

Bill Sibold
President, Chief Executive Officer, Director
Mardi C. Dier
Chief Financial Officer, Senior Vice President
Rebecca A. Taub
President of Research and Development, Chief Medical Officer, Director
Michael R. Charlton
Senior Vice President - Clinical Development
Shannon Kelley
General Counsel
Carole A Huntsman
Chief Commercial Officer
Robert Waltermire
Chief Pharmaceutical Development Officer
Julian C. Baker
Independent Chairman of the Board
Frederick B. Craves
Lead Independent Director
Paul A. Friedman
Director
Kenneth M. Bate
Independent Director
Raymond Cheong
Independent Director
Click to see more

Key facts

  • EPIC
    MDGL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US5588681057
  • Market cap
    $7.09bn
  • Employees
    528
  • Shares in issue
    22.08m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.